UK Head and Neck Cancer Therapeutics Market Report 2023 to 2030

UK Head and Neck Cancer Therapeutics Market Analysis

$ 3999

The UK Head and Neck Cancer Therapeutics Market was valued at $1.96 Mn in 2023 and is predicted to grow at a CAGR of 12.70% from 2023 to 2030, to $4.53 Mn by 2030. The key drivers of this industry include growing cancer incidence, government initiatives, and technological innovations. The industry is primarily dominated by players such as Bristol Myers Squibb, Merck, Roche, and Pfizer among others.

ID: IN10GBPH577 CATEGORY: Pharmaceuticals GEOGRAPHY: UK AUTHOR: Aashwi Mehta

Buy Now

UK Head and Neck Cancer Therapeutics Market Executive Summary

The UK Head and Neck Cancer Therapeutics Market was valued at $1.96 Mn in 2023 and is predicted to grow at a CAGR of 12.70% from 2023 to 2030, to $4.53 Mn by 2030.

Head and neck cancer sites include the squamous cells lining the mucosal surfaces of the head and neck—such as those within the mouth, throat, and larynx (voice box). Head and neck cancers can also start in the salivary glands, sinuses, muscles, or nerves in these areas. Common risk factors include tobacco use, alcohol use, infection with Human Papilloma Virus (HPV), etc. The symptoms of head and neck cancer might include a painful lump in the neck, an ulcer in the mouth or throat that does not go away, trouble swallowing, and a change in voice that sounds hoarse.

The number of new head and neck cancer cases on average each year in the UK is projected to rise from around 14,000 cases in 2023-2025 to around 16,300 cases in 2038-2040. Head and neck cancer incidence rates are projected to rise by 3% in the UK between 2023-2025 and 2038-2040, to 21 cases per 100,000 people on average each year by 2038-2040. The market is driven by significant factors like growing cancer incidence, government initiatives, and technological innovations. However, a shortage of workforce, increasing healthcare expenses, and limited awareness restrict the growth and potential of the market.

Prominent players in this field include Bristol Myers Squibb, Merck, Roche, and Pfizer among others.

UK Head and Neck Cancer Therapeutics Market Report 2023 to 2030

Market Dynamics

Market Growth Drivers

Growing Cancer Incidence: There is an increasing need for effective therapeutic strategies, as seen by the anticipated 3% increase in head and neck cancer incidence rates from 2023-2025 to 2038-2040, reaching 21 cases per 100,000 yearly by that time. This pattern increases consumer demand for innovative treatments and approaches to the UK's rising head and neck cancer rate.

Government Initiatives: Over the next ten years, the NHS Long Term Plan, released in January 2019, lays out ambitious aims to improve cancer outcomes and services in England. A key objective is to achieve a significant increase in the number of individuals surviving cancer for five years or more by 2028, which drives the demand for advancements in head and neck cancer therapeutics in the UK market.

Technological Innovations: The head and neck cancer detection accuracy in the UK is improved by the incorporation of advanced methods including molecular diagnostics and precision medicine. This results in more individualized treatment plans, which in turn boost patient satisfaction and outcomes, driving the therapeutic market forward.

Market Restraints

Shortage of workforce: The Royal College of Radiologist estimates that there is a 15% scarcity of specialized cancer specialists in the UK, with a particular need for clinical oncologists who are in charge of giving chemotherapy and radiation treatment. This difference is expected to grow to 25% by 2027 if nothing is done, which would equate to a 368 full-time consultant shortage. The lack of qualified medical professionals may make it more difficult for patients to receive cancer therapies on time, which could limit the UK's head and neck cancer therapeutics market's expansion.

Increasing Healthcare Expenses: Rising expenses for cancer care, such as those for drugs, procedures, and supportive therapies, can put pressure on healthcare budgets and restrict patients' access to comprehensive treatment, which can act as a market restraint.

Limited Awareness: Limited awareness about head and neck cancer causes delayed diagnoses and decreased treatment-seeking behavior, which restrains the market. Many people might not be aware of the early warning signs or the significance of prompt medical attention, which could lead to advanced-stage diagnoses when therapy is less successful. This lowers the total demand for therapeutic options, limiting the development of the market and the adoption of early, more effective treatment approaches.

Regulatory Landscape and Reimbursement Scenario

The UK government's Medical and Healthcare products Regulatory Agency (MHRA) is in charge of regulating pharmaceuticals and medical devices. The MHRA is in charge of overseeing the regulation of pharmaceuticals, as well as the equipment and devices used in healthcare and conducting investigations into adverse events. The NHS in the UK offers two managed access funds, namely the Cancer Drugs Fund (CDF) and the Innovative Medicines Fund (IMF), which cover expenses for certain advanced or specialized cancer medications, providing reimbursement support to healthcare providers.

Competitive Landscape

Key Players

Here are some of the major key players in the UK Head and Neck Cancer Therapeutic Market:

Bristol Myers Squibb
Merck
Roche
Pfizer
Eli Lilly and Company
AstraZeneca
Novartis
Amgen
GlaxoSmithKline
Sanofi

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

UK Head and Neck Cancer Therapeutics Market Segmentation

By Treatment

Targeted Therapy
Immunotherapy
Radiation Therapy
Surgeries

By End Users

Hospitals
Specialty Centers
Ambulatory Surgical Centers

By Distribution Channel

Hospital-based pharmacies
Retail pharmacies
Online pharmacies

By Route of administration

Injectable
Oral

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.